Medtech innovator Optellum gets €14 million capital injection to improve lung cancer detection
Summary
The medtech startup is aiming to bring about earlier diagnosis of lung cancer, enabling early-stage treatments to be made and patient outcomes improved. Existing investors include St John’s College in the University of Oxford, IQ Capital, and the family office of Sir Martin and Lady Audrey Wood also all participated in this round. In 2021, the medtech company achieved FDA 510(k) clearance and is being used in the UK to predict at-risk lung nodules in a multi-center study with NHS Trusts as part of a major investment in AI for healthcare. This new funding will enable the company to scale its base, operations and commercial launches in the UK and USA, accelerate its research and development, and expand its platform into personalized therapy decisions, integrating imaging with molecular data, robotics, and liquid biopsies. Jason Pesterfield, CEO at Optellum, said: “With this strong support and commitment of highly specialized investors, we are positioned to accelerate commercial deployment in both the UK and the United States to expand our installed base.